Bank of America adds Centene to its “US 1” highest-conviction stock list

Bank of America analysts added Centene Corp. to the firm’s “US 1” highest-conviction list on May 27, according to coverage of the change published June 7. Centene’s ticker is CNC, and the addition reflects a view from Bank of America Global Research that the stock offers an attractive risk-reward profile relative to peers.

The “US 1” list is a dynamic set of research-backed recommendations maintained by Bank of America Global Research, selected from stocks the bank covers and generally marked as “Buy.” In a regulatory-style product profile describing the underlying model, Bank of America says securities can be added to or removed as part of ongoing committee review for fundamental, structural, or tactical reasons.

The same reporting also pointed to Centene’s visibility among investors tracked by public filings. A separate data compilation reported that Centene had 72 hedge-fund holders as of Q1 2026 and was among the top 10 stocks owned by members of Congress. That kind of ownership and holder snapshot does not establish causality with analyst decisions, but it is often cited as a sign of broad market interest.

Centene is a U.S. managed-care company focused on health insurance programs for government-sponsored populations. The company describes itself as serving Medicaid and Medicare beneficiaries, along with individuals and families covered through the Health Insurance Marketplace. Its business profile matters to Wall Street because managed-care results are influenced by government reimbursement rates, enrollment volumes, and medical cost trends.

Analyst-list changes like Bank of America’s are typically treated as indicates about where a firm sees company-specific upside within an established coverage universe. The “US 1” model described by Bank of America also notes that the strategy can be less diversified than broad benchmarks, which means the performance of the basket can be more sensitive to individual-stock outcomes.

Still, what Bank of America disclosed in the immediate announcement itself is limited. The May 27 “US 1” addition and any implied rationale were summarized in market-news reporting rather than laid out in a full investor presentation or earnings release. Bank of America’s product profile describes the selection framework but does not provide company-by-company, quarter-specific underwriting details for why Centene was selected at that point in time.

For Centene, the next datapoints that could help confirm whether the analyst conviction is strengthening or merely shifting are company updates tied to membership and medical-cost trends, as well as any follow-on research notes from other large brokers. In the near term, investors will also likely watch whether Bank of America makes further changes to the US 1 list around concurrent calls and sector moves, since the model’s holdings can turnover as committees rebalance.